JP2008531739A5 - - Google Patents

Download PDF

Info

Publication number
JP2008531739A5
JP2008531739A5 JP2008500016A JP2008500016A JP2008531739A5 JP 2008531739 A5 JP2008531739 A5 JP 2008531739A5 JP 2008500016 A JP2008500016 A JP 2008500016A JP 2008500016 A JP2008500016 A JP 2008500016A JP 2008531739 A5 JP2008531739 A5 JP 2008531739A5
Authority
JP
Japan
Prior art keywords
cancer
cells
composition
cell
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008500016A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008531739A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2006/000315 external-priority patent/WO2006094385A1/en
Publication of JP2008531739A publication Critical patent/JP2008531739A/ja
Publication of JP2008531739A5 publication Critical patent/JP2008531739A5/ja
Pending legal-status Critical Current

Links

JP2008500016A 2005-03-07 2006-03-06 治療的処置のための粘液腫ウイルスとラパマイシンの組み合わせの使用 Pending JP2008531739A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65881605P 2005-03-07 2005-03-07
PCT/CA2006/000315 WO2006094385A1 (en) 2005-03-07 2006-03-06 Use of a combination of myxoma virus and rapamycin for therapeutic treatment

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012197457A Division JP5674210B2 (ja) 2005-03-07 2012-09-07 治療的処置のための粘液腫ウイルスとラパマイシンの組み合わせの使用

Publications (2)

Publication Number Publication Date
JP2008531739A JP2008531739A (ja) 2008-08-14
JP2008531739A5 true JP2008531739A5 (cg-RX-API-DMAC10.html) 2009-04-16

Family

ID=36952904

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2008500016A Pending JP2008531739A (ja) 2005-03-07 2006-03-06 治療的処置のための粘液腫ウイルスとラパマイシンの組み合わせの使用
JP2012197457A Expired - Fee Related JP5674210B2 (ja) 2005-03-07 2012-09-07 治療的処置のための粘液腫ウイルスとラパマイシンの組み合わせの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012197457A Expired - Fee Related JP5674210B2 (ja) 2005-03-07 2012-09-07 治療的処置のための粘液腫ウイルスとラパマイシンの組み合わせの使用

Country Status (14)

Country Link
US (5) US20090035276A1 (cg-RX-API-DMAC10.html)
EP (2) EP2388315B1 (cg-RX-API-DMAC10.html)
JP (2) JP2008531739A (cg-RX-API-DMAC10.html)
KR (1) KR101479093B1 (cg-RX-API-DMAC10.html)
CN (2) CN101137748B (cg-RX-API-DMAC10.html)
AU (1) AU2006222500B2 (cg-RX-API-DMAC10.html)
CA (1) CA2600675C (cg-RX-API-DMAC10.html)
DK (1) DK2388315T3 (cg-RX-API-DMAC10.html)
IL (2) IL185376A0 (cg-RX-API-DMAC10.html)
MX (1) MX2007010962A (cg-RX-API-DMAC10.html)
NZ (2) NZ577283A (cg-RX-API-DMAC10.html)
RU (1) RU2461630C2 (cg-RX-API-DMAC10.html)
UA (1) UA96412C2 (cg-RX-API-DMAC10.html)
WO (1) WO2006094385A1 (cg-RX-API-DMAC10.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2388315T3 (da) 2005-03-07 2014-08-25 Univ Western Ontario Anvendelse af et myxomvirus, som ikke eksprimerer funktionelt M135R, til terapeutisk behandling
US8512713B2 (en) * 2006-06-01 2013-08-20 Robarts Research Institute Myxoma virus mutants for cancer treatment
CN102124335B (zh) * 2008-05-22 2014-07-30 第一药品株式会社 基于肿瘤抑制因子的过度增生细胞对溶瘤病毒疗法的敏感性
US20120100109A1 (en) * 2010-10-26 2012-04-26 Xiaoliu Zhang Method for increasing the replication of oncolytic HSVs in highly resistant tumor cells using mTOR pathway and PI3K inhibitors
EP2717887B1 (en) * 2011-06-09 2017-12-27 University of Florida Research Foundation, Inc. Methods for treating or preventing graft versus host disease
RU2695136C1 (ru) * 2018-06-19 2019-07-22 Общество с ограниченной ответственностью Биотехнология (ООО Биотехнология) Онколитический способ терапии рака молочной железы.
WO2020033510A1 (en) * 2018-08-08 2020-02-13 Arizona Board Of Regents On Behalf Of Arizona State University Method for improved poxvirus yields
CA3112788A1 (en) 2018-09-05 2020-03-12 Arizona Board Of Regents On Behalf Of Arizona State University Oncolytic virus platform to treat hematological cancer
CA3152787A1 (en) 2019-09-02 2021-03-11 Arizona Board Of Regents On Behalf Of Arizona State University Methods and compositions for improving oncolytic virus infection for nonpermissive cancers
CN114828861A (zh) * 2019-10-10 2022-07-29 亚利桑那州立大学董事会 表达多特异性免疫细胞接合器的溶瘤病毒
US20240091284A1 (en) * 2019-10-10 2024-03-21 Arizona Board Of Regents On Behalf Of Arizona State University Oncolytic virus comprising immunomodulatory transgenes and uses thereof
WO2022139440A1 (ko) * 2020-12-22 2022-06-30 바이로큐어 주식회사 신규한 재조합 믹소마바이러스 및 이의 용도

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4401653A (en) * 1981-03-09 1983-08-30 Ayerst, Mckenna & Harrison Inc. Combination of rapamycin and picibanil for the treatment of tumors
US4806347A (en) 1985-12-11 1989-02-21 Schering Corporation Interferon combinations
GB9415320D0 (en) 1994-07-29 1994-09-21 Medical Res Council Cancer treatment
EP1314430A1 (en) 1996-01-25 2003-05-28 The University Court Of The University Of Glasgow Treatment of non-neuronal cancer using HSV mutant
EP1003894A2 (en) 1997-07-18 2000-05-31 Chiron Corporation Lentiviral vectors
US7041654B2 (en) * 1997-10-03 2006-05-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Methods and compositions for inducing tumor-specific cytotoxicity
EP1905304A3 (en) 1997-10-09 2008-08-13 Wellstat Biologics Corporation Treatment of neoplasms with viruses
US6264940B1 (en) * 1998-08-05 2001-07-24 The Research Foundation Of State University Of New York Recombinant poliovirus for the treatment of cancer
AU6175000A (en) 1999-07-12 2001-01-30 Viron Therapeutics, Inc. Novel myxoma genes for immune modulation
BR0015491A (pt) * 1999-11-12 2002-10-15 Oncolytics Biotech Inc Métodos para tratar um distúrbio proliferativo celular mediado por ras em um mamìfero, para tratar um neoplasma tendo uma via-ras ativada em um humano, para inibir metástase de um neoplasma tendo uma via-ras ativada em um mamìfero, e para tratar um neoplasma suspeito de ter uma via-ras ativada em um mamìfero, composição farmacêutica, kit, e, método para tratar uma população de células compreendendo um neoplasma suspeito de ter uma via-ras ativada in vitro
WO2001087324A1 (en) * 2000-05-17 2001-11-22 Viron Therapeutics, Inc. Compositions and methods for promoting immunosuppression
CN1551767A (zh) * 2001-02-19 2004-12-01 ��˹��ŵ�� 癌症的治疗
UA77200C2 (en) * 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569
WO2004014314A2 (en) * 2002-08-12 2004-02-19 David Kirn Methods and compositions concerning poxviruses and cancer
WO2004078206A1 (en) * 2003-03-07 2004-09-16 Robarts Research Institute Use of myxoma virus for the therapeutic treatment of cancer and chronic viral infection
KR20060006058A (ko) * 2003-04-22 2006-01-18 와이어쓰 항신생물성 배합물
WO2005002607A2 (en) * 2003-07-07 2005-01-13 Oncolytics Biotech Inc. Oncolytic reoviruses for the treatment of neoplasms having activated pp2a or rac
US20070207149A1 (en) * 2004-04-27 2007-09-06 Wellstat Biologics Corporation Cancer treatment using viruses and camptothecins
DK2388315T3 (da) 2005-03-07 2014-08-25 Univ Western Ontario Anvendelse af et myxomvirus, som ikke eksprimerer funktionelt M135R, til terapeutisk behandling

Similar Documents

Publication Publication Date Title
JP2011157399A5 (cg-RX-API-DMAC10.html)
Rodrigues et al. Pathogenesis of cholangiocarcinoma
Cai et al. Alantolactone: a natural plant extract as a potential therapeutic agent for cancer
JP2012517427A5 (cg-RX-API-DMAC10.html)
JP2014530874A5 (cg-RX-API-DMAC10.html)
JP2011500713A5 (cg-RX-API-DMAC10.html)
JP2013527232A5 (cg-RX-API-DMAC10.html)
JP2015536964A5 (cg-RX-API-DMAC10.html)
JP2008535785A5 (cg-RX-API-DMAC10.html)
CA2517147A1 (en) Use of myxoma virus for the therapeutic treatment of cancer and chronic viral infection
Rani et al. Acetamides: chemotherapeutic agents for inflammation-associated cancers
JP2013518124A5 (cg-RX-API-DMAC10.html)
TR201109804A2 (tr) Tek dozlu inhalasyon cihazı.
JP2016501528A5 (cg-RX-API-DMAC10.html)
WO2021218965A1 (zh) 茜草科类型环肽化合物在制备cGAS-STING信号通路激活剂的药物中的应用
Yongprayoon et al. Targeting BRD4: Potential therapeutic strategy for head and neck squamous cell carcinoma
RU2007137008A (ru) Применение комбинации вируса миксомы и рапамицина для терапевтического лечения
Habeeb et al. Strategies of cell signaling and critical focus on etiology of hepatocellular carcinoma
Voiculescu et al. Chemotherapies and targeted therapies in advanced hepatocellular carcinoma: from laboratory to clinic
CN109498629A (zh) 一种小分子抑制剂用于结直肠癌化疗敏感性的应用
JP2011500650A5 (cg-RX-API-DMAC10.html)
JP2020509035A5 (cg-RX-API-DMAC10.html)
Singh et al. Molecular chemotherapy and chemotherapy: a new front against late-stage hormone-refractory prostate cancer
CN103096885A (zh) 不饱和脂肪酸用于抑制病毒复制和/或感染的用途
JP2014177492A5 (cg-RX-API-DMAC10.html)